Effect of Albendazole and steroids vs steroids alone on whole body MRI in disseminated cysticercosis patients.

Quantitative assessment of cysticercosis on whole body MRI in patients with disseminated cysticercosis treated with albendazole with steroids vs steroids alone and outcome assessment at 3 months a randomized controlled trial

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/12/048558

Enrollment

Registered

2022-12-28

Start date

Unknown

Completion date

Unknown

Last updated

2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B699- Cysticercosis, unspecified

Interventions

Intervention1: ALBENDAZOLE WITH STEROIDS(ORAL METHYLPREDNISOLONE): ALBENDAZOLE(15mg/kg body weight) ONE CYCLE (14 days) WITH STEROIDS(ORAL METHYLPREDNISOLONE-0.75-1mg/kg body weight to start 3 days be

Eligibility

Inclusion criteria

Inclusion criteria: All the cases of disseminated cysticercosis Disseminated cysticercosis will be diagnosed as >= 3 NCC with involvement of at least one extra site like subcutaneous tissues, skeletal muscles, eyes, or presence in any visceral organ. Patients of neurocysticercosis will be diagnosed on the basis of Del Brutto criteria.

Exclusion criteria

Exclusion criteria: 1) Patient in cysticercal encephalitis. 2) Patient with subretinal cysticercosis. 3) Patients having evidence of systemic illness as malignancy, Tuberculosis, HIV etc 4) Patients with hypersensitivity to albendazole 5) Patients with alcohol /substance abuse 6) Patients with primary psychiatric disease prior to developing neurocysticercosis 7) Pregnant females 8) Patients/ attendants refusing consent

Design outcomes

Primary

Measure	Time frame
To asess lesion reduction in patients with Disseminated Cysticercosis on Whole body MRI at 3 months of treatment as per protocolTimepoint: To asess lesion reduction in patients with Disseminated Cysticercosis on Whole body MRI at 3 months of treatment as per protocol	—

Secondary

Measure	Time frame
To asess quality of life in patients with Disseminated Cysticercosis at baseline and at 3 months of treatment as per protocolTimepoint: At baseline and at 3 months of treatment	—

Countries

India

Contacts

Public ContactDr Jadhav Padmajeet Ranjeetsinh

Department of Neurology

drneeraj2903@gmail.com919450357392

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026